Biotech giants advance bispecific antibodies for lung cancer amid FDA’s accelerated approval push, revealing structural gaps in equitable access and long-term efficacy data
Original framing: “STAT+: BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA” — STAT News
Marginalised communities, including Black, Indigenous, and low-income populations, are systematically underrepresented in clinical trials for bispecific antibodies, despite bearing a disproportionate burden of lung cancer mortality. This exclusion perpetuates health disparities and ensures that therapies are not optimised for the populations most in need. Additionally, the high cost of these drugs—often exceeding $200,000 per year—further entrenches inequality, as insurers and governments in low-income countries cannot afford to cover them, leaving patients to choose between bankruptcy and untreated disease.
The Pfizer/BioNTech bispecific antibody narrative exemplifies how corporate-driven innovation in oncology is framed as a triumph of modern science, while systemic failures—regulatory capture, racial and economic inequities, and the erasure of alternative medical systems—are obscured.
The FDA’s accelerated approval pathway, championed by Rick Pazdur, has become a mechanism for legitimising high-cost, marginally effective drugs under the guise of 'patient access,' a dynamic reminiscent of past regulatory failures like the 1990s cytokine therapy hype. Meanwhile, marginalised communities, who bear the brunt of lung cancer mortality, are excluded from the clinical trials that define these therapies, ensuring that the benefits remain concentrated among the global elite. Cross-culturally, the focus on bispecific antibodies ignores the success of alternative models, such as Cuba’s state-led biotech industry or the integration of traditional medicine in countries like China and India, which have achieved comparable outcomes at a fraction of the cost. The solution lies not in rejecting innovation but in reorienting it toward equity: mandatory inclusive trials, global pooled procurement, and the integration of traditional knowledge could transform bispecific antibodies from a symbol of inequity into a tool for global health justice.